Business UpdateJun 8, 2026, 04:07 PM
Vor Biopharma: Telitacicept approved in China for IgA Nephropathy & Sjögren's Disease
AI Summary
Vor Biopharma Inc. announced that its collaborator, RemeGen Co., Ltd., has received conditional approval from China's National Medicinal Products Administration (NMPA) for telitacicept to treat adult patients with IgA nephropathy (IgAN). Additionally, RemeGen received NMPA approval for telitacicept for adult patients with Sjögren's disease in China. These approvals mark significant milestones for telitacicept, a therapy targeting BAFF/APRIL, which Vor Bio is developing globally outside of Greater China.
Key Highlights
- Vor Biopharma's collaborator RemeGen received conditional NMPA approval for telitacicept in China for IgA nephropathy.
- RemeGen also received NMPA approval for telitacicept in China for Sjögren's disease.
- Telitacicept is a novel recombinant fusion protein targeting BAFF/APRIL for autoimmune diseases.
- The IgA nephropathy approval is based on positive Phase 3 TELIGAN trial results published in The New England Journal of Medicine.
- The Sjögren's disease approval is based on positive Phase 3 clinical program results demonstrating improvements in ESSDAI and ESSPRI.
- Vor Bio holds exclusive rights to develop and commercialize telitacicept outside of Greater China.
Price Impact
More from VOR